MondoA is highly overexpressed in acute lymphoblastic leukemia cells and modulates their metabolism, differentiation and survival.
Leuk Res, 2012/9;36(9):1185-92.
Wernicke CM[1], Richter GH, Beinvogl BC, Plehm S, Schlitter AM, Bandapalli OR, Prazeres da Costa O, Hattenhorst UE, Volkmer I, Staege MS, Esposito I, Burdach S, Grunewald TG
Affiliations
PMID: 22748921DOI: 10.1016/j.leukres.2012.05.009
Impact factor: 3.715
Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. To identify novel candidates for targeted therapy, we performed a comprehensive transcriptome analysis identifying MondoA (MLXIP) - a transcription factor regulating glycolysis - to be overexpressed in ALL compared to normal tissues. Using microarray-profiling, gene-set enrichment analysis, RNA interference and functional assays we show that MondoA overexpression increases glucose catabolism and maintains a more immature phenotype, which is associated with enhanced survival and clonogenicity of leukemia cells. These data point to an important contribution of MondoA to leukemia aggressiveness and make MondoA a potential candidate for targeted treatment of ALL.
MeSH terms
Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Differentiation; Cell Survival; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hep G2 Cells; Humans; Jurkat Cells; Microarray Analysis; Neoplasm Invasiveness; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Small Interfering; Tumor Cells, Cultured; Up-Regulation
More resources
EndNote: Download